Background: Previous studies have suggested a correlation between the occurrence of vasomotor or joint symptoms during tamoxifen or aromatase inhibitor treatment and improved clinical response.
menopausal symptoms or arthralgia/myalgia showed that OS and DFS were significantly improved in patients reporting one of these symptoms versus those not reporting either symptom.
Conclusion:
The occurrence of arthralgia/myalgia or menopausal symptoms during endocrine treatment is associated with significantly improved OS. Key words: adverse events, arthralgia, exemestane, myalgia, postmenopausal, tamoxifen introduction Endocrine therapy is recommended as adjuvant treatment for postmenopausal patients with hormone receptor-positive early breast cancer [1, 2] . Tamoxifen has been the standard adjuvant endocrine treatment for many years; however, in recent years, aromatase inhibitors (AIs) have demonstrated equivalent or superior efficacy to tamoxifen in several trials [3] [4] [5] . Treatment guidelines now recommend that adjuvant endocrine treatment includes an AI [1] .
Commonly reported adverse events (AEs) associated with AIs and tamoxifen include those related to estrogen deprivation, such as hot flushes, night sweats, arthralgia and myalgia [3] [4] [5] [6] [7] . While tamoxifen is a selective estrogen receptor modulator and interferes with the binding of estrogen to its receptor [8] , AIs inhibit the conversion of androgens to estrogen [9] . As a result of these differences in their mechanisms of action, tamoxifen and AIs are associated with distinct AE profiles. Treatment with tamoxifen has been associated with gynecological AEs, including vaginal bleeding and endometrial cancer. Furthermore, thromboembolic events have been associated with tamoxifen treatment [3] [4] [5] [6] [7] . In contrast, patients receiving AIs are more likely to suffer from musculoskeletal AEs, including arthralgia and myalgia [10] . AI treatment has also been associated with an accelerated rate of bone loss [11, 12] and the incidence of fractures is increased with AI versus tamoxifen treatment [3] [4] [5] [6] [7] . Furthermore, AI treatment has been associated with an increase in cardiovascular AEs versus tamoxifen treatment [13] .
With some drugs, the occurrence of specific AEs has been shown to predict treatment response. For example, in patients treated with epidermal growth factor receptor agents, the incidence and severity of rash have been shown to be associated with improved clinical outcomes [14, 15] . Previous studies have suggested that the occurrence of hot flashes during tamoxifen treatment may be associated with reduced recurrence of breast cancer [16] .
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial was a phase III randomized open-label trial which compared 5 years' exemestane with 2.5-3 years' tamoxifen followed by 2-2.5 years' exemestane in postmenopausal women with hormone receptor-positive early breast cancer [17] . TEAM was initially designed to assess 5 years' exemestane versus 5 years' tamoxifen. However, results from the Intergroup Exemestane Study showed that switching to exemestane following 2-3 years of tamoxifen significantly improved disease-free survival (DFS) compared with continuing tamoxifen. As such, the study design was amended [17] . The final analysis of TEAM, at a median follow-up of 5 years, demonstrated that there were no significant differences in efficacy between 5 years' exemestane and the sequence of tamoxifen followed by exemestane [17] . The authors concluded that exemestane monotherapy or sequential therapy were appropriate treatment options and that consideration of safety profiles would be important when making treatment decisions. We performed a retrospective analysis of the German cohort of the TEAM trial to investigate if the occurrence of specific treatment-emergent AEs was associated with clinical response to treatment with either sequential treatment or exemestane.
methods
All patients provided written informed consent. The study was approved by the local ethics committees and was conducted in accordance with the Declaration of Helsinki.
study design and treatment
The TEAM trial was a phase III, randomized open-label trial in which postmenopausal women with hormone receptor-positive early breast cancer were randomly assigned 1:1 to receive 25 mg of exemestane daily for 5 years or tamoxifen 20 mg daily for 2.5-3 years followed by 2-2.5 years of exemestane. The TEAM trial was conducted in nine countries (Belgium, France, Germany, Greece, Ireland, Japan, The Netherlands, the UK and the United States). This was a retrospective analysis of all patients enrolled in the German cohort of the TEAM trial, to assess if there was any correlation between specific AEs and clinical outcome.
Modifications to dose or schedule were not permitted. Patients discontinued study drug if the investigator considered it was medically necessary, unacceptable toxicity was experienced, consent was withdrawn or relapse of disease occurred. All patients were followed up, whether or not they discontinued treatment. Adjuvant hormonal treatment was initiated within 14 weeks after completion of surgery. Patients completed a 'Drug Administration Record' at home, which was brought to each clinic visit to document treatment compliance. Further details on the trial design, methods and primary and secondary objectives of the TEAM trial have been published elsewhere [17] .
assessments
During the first year of treatment, patients were assessed every 3 months and at least once yearly thereafter; mammography was carried out annually. AEs were recorded at each visit. Data on AEs were obtained using elicited responses and prespecified checklists were not used. Pre-existing AEs were only included if they worsened following the first dose of study drug. Severity was assessed by the investigators, based on the National Cancer Institute-Common Toxicity Criteria, version 2.0. Investigators also assessed the relationship between AEs and treatment.
For this retrospective analysis, AEs of interest included incidence of arthralgia or myalgia, occurrence of fractures and menopausal symptoms. These measured symptoms were defined as of interest before the analysis. In accordance with international guidelines, menopausal symptoms were defined as: hot flashes/flushes; constitutional symptoms, including difficulties sleeping, disorders of sleep, sleeping disturbances, sleeplessness, trouble with sleep, worsening sleep disturbance; insomnia; mood alteration-anxiety, agitation; mood alteration-depression; depressed level of 
end points
The occurrence of arthralgia and myalgia, fractures and menopausal symptoms were assessed. End points for this analysis were DFS and OS in patients with and without arthralgia and myalgia and those with and without menopausal symptoms after 5 years of treatment.
statistical analysis
All randomized patients who started treatment were included in the intention-to-treat population. The intention-to-treat population was used for all efficacy analyses. Kaplan-Meier estimates were used to calculate the occurrence of arthralgia or myalgia, fractures and menopausal symptoms. Kaplan-Meier estimates were also used to calculate OS and DFS in patients with and without arthralgia/myalgia, those with and without menopausal symptoms and those with and without either symptom. Cox regression analyses were carried out to assess the effect of baseline characteristics and these AEs on OS and DFS. Efficacy and safety end points were compared using log-rank tests and all P values were two-sided. P values < 0.05 were considered statistically significant. All database management and statistical analyses were carried out using the Statistical Analysis System, version 9.1.
results patient characteristics
A total of 1525 patients were randomized to sequential therapy (n = 752) or exemestane alone (n = 773). A total of 23 patients did not start treatment; therefore, 739 patients and 763 patients were included in this analysis, respectively (supplemental Figure S1 , available at Annals of Oncology online). Patients in the sequential arm switched to exemestane after 2.5-3 years of tamoxifen treatment.
Overall, baseline characteristics of patients were similar across treatment groups (Table 1) ; however, the number of patients with stage 4 disease was significantly higher in the sequential arm. The incidence of arthralgia or myalgia, fracture and menopausal symptoms at baseline was similar between groups ( Table 2) .
incidence of arthralgia or myalgia, fracture and menopausal symptoms during treatment Exemestane was associated with significantly more arthralgia or myalgia versus tamoxifen during the first 2.5 years of treatment (P < 0.0001; supplemental Figure S2A , available at Annals of Oncology online). When the occurrence of arthralgia or myalgia was evaluated over time (Table 2) , significantly more patients receiving exemestane reported arthralgia or myalgia compared with those receiving tamoxifen between the beginning of treatment and until 30 months of treatment. At the time when patients receiving tamoxifen switched to exemestane (month 30 onwards), there were no significant differences in arthralgia or myalgia between groups.
Overall, the incidence of fracture was not significantly different between treatment groups during the first 2.5 years of treatment (P = 0.4; data not shown). The occurrence of fractures during the 5 years of treatment is shown in Table 2 . There were significantly more fractures in the exemestane alone group than the sequential treatment arm during month 30 onwards (Table 2) . Menopausal symptoms were commonly reported during tamoxifen and exemestane treatment ( Table 2) . During the first 2.5 years' treatment, more patients receiving tamoxifen reported menopausal symptoms than those receiving exemestane; however, this difference was not significant (P = 0.1; supplemental Figure S2B , available at Annals of Oncology online). The incidence of either menopausal symptoms or arthralgia/myalgia was not significantly different between treatment groups (P = 0.3; supplemental Figure S2C , available in Annals of Oncology online).
OS and DFS in patients with and without arthralgia/ myalgia
In the total patient population, patients who experienced arthralgia/myalgia had significantly longer OS [hazard ratio (HR) 3.6, 95% CI 2.0-6.6; P < 0.0001; Figure 1A ] than those who did not report these symptoms. The improvement in OS was irrespective of treatment, with OS significantly improved in both sequential-and exemestane-treated patients reporting arthralgia/myalgia versus those with no arthralgia/myalgia (HR 4.5, 95% CI 1.6-12.6; P < 0.01 and HR 3.1, 95% CI 1.5-6.7; P < 0.01; Table 3 ).
In the total patient population, patients who experienced arthralgia/myalgia had significantly longer DFS (HR 2.0, 95% CI 1.4-2.9; P < 0.001; Figure 1B ) than those who did not report these symptoms. There was no difference in DFS in patients receiving sequential treatment with or without arthralgia/ myalgia (HR 1.3, 95% CI 0.8-2.2; P = 0.3). DFS was significantly improved in exemestane-treated patients with arthralgia/myalgia versus those without this AE (HR 2.9, 95% CI 1.6-5.2; P < 0.001; Table 3 ).
OS and DFS in patients with and without menopausal symptoms
In the total patient population, OS was significantly longer in patients reporting menopausal symptoms compared with those who did not report menopausal symptoms (HR 2.5, 95% CI 1.7-3.9; P < .0001; Figure 2A ). OS was significantly improved in both sequential-and exemestane-treated patients who experienced menopausal symptoms versus those who did not report these symptoms (HR 2.5, 95% CI 1.4-4.4; P < 0.01 and HR 2.7, 95% CI 1.4-5.0; P < 0.01, respectively; Table 3 ).
Similarly, DFS was significantly longer in patients reporting menopausal symptoms compared with those who did not report these symptoms (HR 1.5, 95% CI 1.1-2.0; P = 0.01; Figure 2B ). There was no significant difference in DFS between patients receiving sequential therapy with or without menopausal symptoms (HR 1.2, 95% CI 0.8-1.9; P = 0.3). Exemestane-treated patients reporting menopausal symptoms had significantly longer DFS than those not reporting menopausal symptoms (HR 1.9, 95% CI 1.2-3.0; P < 0.01; Table 3 ). combined analysis of OS and DFS in patients with and without arthralgia/myalgia or menopausal symptoms OS and DFS were significantly improved in patients with either arthralgia/myalgia or menopausal symptoms versus patients without these symptoms (HR 3.0, 95% CI 2.0-4.4; P < 0.0001 and HR 2.0, 95% CI 1.5-2.8; P < 0.0001; OS: Figure 3 ). OS and DFS in sequential-and exemestane-treated patients were significantly improved in patients with arthralgia/myalgia or menopausal symptoms versus those not reporting these AEs (Table 3) .
Cox regression analysis
A small but significant correlation between the occurrence of arthralgia/myalgia and age was observed. Age, tumor stage and incidence of arthralgia/myalgia were significantly correlated with OS. Tumor stage and incidence of arthralgia/myalgia were significantly correlated with DFS (data not shown), supporting the results from the Kaplan-Meier analysis. A significant correlation between age and occurrence of menopausal symptoms was observed. No significant effect of the occurrence of menopausal symptoms and OS or DFS was observed in this analysis (data not shown).
discussion
Our retrospective analysis of the German cohort of the TEAM trial suggested that patients reporting arthralgia/myalgia and those reporting menopausal symptoms had significantly longer DFS and OS than patients who did not report these AEs. The effect on OS was irrespective of treatment. A significant improvement in DFS was observed in exemestane-treated patients reporting arthralgia/myalgia or those reporting menopausal symptoms versus those not reporting these AEs. However, in patients receiving sequential therapy, there was no significant difference in DFS between those reporting arthralgia/myalgia or those reporting menopausal symptoms versus those not reporting these AEs. A combined analysis of patients with either arthralgia/myalgia or menopausal symptoms showed that OS and DFS were significantly improved in patients reporting one of these symptoms versus those not experiencing either symptom. In this analysis, the effect on OS and DFS was irrespective of treatment.
The occurrence of specific AEs has been shown to be associated with improved clinical response with other treatments. For example, the occurrence of hypothyroidism has been shown to be associated with improved clinical outcome in patients with head and neck cancer [18] . Hypertension during sunitinib treatment has also been associated with improved outcome [19] .
Similar to our study, a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial showed that both anastrozole-, a nonsteroidal AI, and tamoxifen-treated patients who experienced either vasomotor or joint symptoms within the first 3 months of treatment had significantly fewer breast cancer recurrences than those who did not report symptoms [20] . In this analysis, the effect was larger in patients reporting joint symptoms [adjusted HR 0.60 (95% CI 0.50-0.72); P < 0.0001] than those reporting vasomotor symptoms [adjusted HR: 0.84 (95% CI: 0.71-1.00); P = 0.04] [20] . In patients reporting vasomotor symptoms, the effect was mainly observed in patients who had previously received hormone replacement therapy [20] .
Furthermore, a previous study with patients receiving tamoxifen suggested that patients who reported hot flashes were significantly less likely to experience breast cancer recurrence than those who did not report hot flashes (P = 0.01) original articles Annals of Oncology [16] . It was suggested that this may be due to the role of cytochrome P450 (CYP) 2D6 which converts tamoxifen to its active metabolite, endoxifen. Some polymorphisms of CYP2D6 can result in a less active enzyme. Previous studies in breast cancer patients receiving tamoxifen have suggested that women with impaired CYP2D6 metabolism have a higher risk of recurrence than extensive metabolizers [21, 22] . In addition, one study showed that patients who were homozygous for CYP2D6*4 (the most common allele associated with poor metabolism) had a higher risk of breast cancer recurrence and a lower incidence of hot flashes [23] . However, this topic remains a matter of much debate.
In our study, there did appear to be a correlation between patients reporting menopausal symptoms and improved OS for tamoxifen. However, a similar correlation was also observed for the AI, exemestane. Similarly, in the retrospective analysis of the ATAC trial, there was a link between vasomotor symptoms and improved clinical outcome for anastrozole-treated patients [20] . As AIs are not affected by CYP2D6 metabolism, this would suggest that other factors may be involved.
In contrast with our results and those from the ATAC trial, a recent exploratory analysis of the NCIC CTG MA.27 trial, which randomized patients to 5 years' adjuvant therapy with anastrozole or exemestane, reported no significant difference in DFS between patients experiencing or not experiencing vasomotor or joint symptoms, when evaluating the occurrence of symptoms after 3, 6 and 12 months of treatment [24] .
Menopausal symptoms and joint symptoms are commonly reported in patients receiving endocrine therapy for breast cancer and are thought to be related to estrogen deprivation. As such, it may be that a greater reduction in estrogen levels offers more effective inhibition of the estrogen receptor-positive breast cancer tumor but also may result in increased menopausal symptoms and joint symptoms due to a near total estrogen deprivation. It is also important to consider that there was no significant correlation between patients reporting arthralgia/myalgia or those reporting menopausal symptoms and improved DFS for the sequential treatment group. The reasons for this disparity between treatment groups are unclear; however, we may hypothesize that this could be caused by the total estrogen suppression observed with exemestane consequently leading to arthralgia/myalgia, as well as menopausal symptoms. In contrast, tamoxifen acts as a partial agonist/antagonist and may not lead to the same of extent of symptoms. As such, further research into the mechanisms behind the correlation of the occurrence of menopausal symptoms and joint symptoms and response to endocrine therapy in patients with hormone receptor-positive breast cancer is required.
It is also important to note that AEs, such as arthralgia/ myalgia and menopausal symptoms, may lead patients to discontinue treatment and result in poor adherence to therapy. Indeed, adherence to endocrine therapy has been shown to be suboptimal, potentially reducing the efficacy of therapy [25, 26] . Our results, in addition to those reported by the ATAC trial, may help reassure patients and encourage them to continue therapy, thereby improving adherence [27, 28] . Our results may also raise questions regarding the appropriateness of treating these AEs, as this may also affect the efficacy of endocrine therapy. However, further investigation regarding this is required and currently, it does seem appropriate to treat arthralgias and menopausal symptoms in patients who are suffering from these AEs.
Limitations of our study include the inaccuracy of coding AEs and serious AEs in clinical trials, as well as the small (n = 1502) patient population. Additionally, we have restricted this analysis to the German cohort, due to the different practice of coding AEs within different countries participating in TEAM. In addition, it is important to note that this was a retrospective analysis, and, as such, caution should be applied when interpreting these results. It should also be considered that the occurrence of arthralgia/ myalgia was more frequent in the exemestane group compared with the sequential group during the first 30 months of treatment, which may have affected the results.
In conclusion, our results suggest that the occurrence of arthralgia/myalgia or menopausal symptoms during treatment with either tamoxifen followed by an AI or an AI alone is associated with significant improvements in OS. 
